MMAF sodium
Based on 8 publication(s) in Google Scholar
MMAF sodium (Monomethylauristatin F sodium) is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF sodium (Monomethylauristatin F sodium) is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as Vorsetuzumab mafodotin and SGN-CD19A.
For research use only. We do not sell to patients.
- Purity: 99.59%
- CAS No.: 1799706-65-2
- Formula: C39H64N5NaO8
- Molecular Weight:753.94
-
Storage:
4°C, protect from light, stored under nitrogen
* The compound is unstable in solutions, freshly prepared is recommended.
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) MMAF sodium
More- J Control Release. 2018 May 10;277:48-56. [Abstract]
- Mol Ther Nucleic Acids. 2018 Mar 2;10:227-236. [Abstract]
- Mol Cancer Ther. 2023 Apr 3;22(4):459-470. [Abstract]
- Target Oncol. 2019 Oct;14(5):577-590. [Abstract]
- Oncol Rep. 2021 Feb;45(2):776-785. [Abstract]
- Research Square Preprint. 2023 Dec 4.
- University of Minnesota. 2022 Sep.
- Patent. US20210393733A1.
Biological Activity
|
Auristatin |
MMAF inhibits anaplastic large cell lymphoma Karpas 299, breast carcinoma H3396, renal cell carcinoma 786-O and Caki-1 cells with IC50s of 119, 105, 257 and 200 nM in vitro cytotoxicity assay[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 1799706-65-2
-
Appearance Solid
-
Molecular Weight 753.94
-
Formula C39H64N5NaO8
-
Color White to off-white
-
SMILES
CC[C@H](C)[C@@H]([C@@H](CC(N1[C@@H](CCC1)[C@@H]([C@@H](C)C(N[C@H](C(O[Na])=O)CC2=CC=CC=C2)=O)OC)=O)OC)N(C([C@H](C(C)C)NC([C@H](C(C)C)NC)=O)=O)C
-
Synonyms
Monomethylauristatin F sodium
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, protect from light, stored under nitrogen
* The compound is unstable in solutions, freshly prepared is recommended.
Publications (8)
-
Journal Impact Factor
-
Most Recent
-
J Control Release
EV20-mediated delivery of cytotoxic auristatin MMAF exhibits potent therapeutic efficacy in cutaneous melanoma. [Abstract]2018 May 10;277:48-56. PMID: 29550398 -
Mol Ther Nucleic Acids
2018 Mar 2;10:227-236. PMID: 29499935 -
Mol Cancer Ther
Payload-binding Fab fragments increase the therapeutic index of MMAE antibody-drug conjugates. [Abstract]2023 Apr 3;22(4):459-470. PMID: 36723609 -
Target Oncol
Therapeutic Targeting of Golgi Phosphoprotein 2 (GOLPH2) with Armed Antibodies: A Preclinical Study of Anti-GOLPH2 Antibody Drug Conjugates in Lung and Colorectal Cancer Models of Patient Derived Xenografts (PDX). [Abstract]2019 Oct;14(5):577-590. PMID: 31541350 -
Oncol Rep
EV20‑sss‑vc/MMAF, an HER‑3 targeting antibody‑drug conjugate displays antitumor activity in liver cancer. [Abstract]2021 Feb;45(2):776-785. PMID: 33416143 -
-
-
Solvent & Solubility
DMSO : ≥ 200 mg/mL (265.27 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : ≥ 100 mg/mL (132.64 mM)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 5 mg/mL (6.63 mM); Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 5 mg/mL (6.63 mM); Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
Purity & Documentation
-
Data Sheet (278 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Lee JW, et al. EphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinoma. Clin Cancer Res. 2010 May 1;16(9):2562-70. [Content Brief]
[2]. Lee JJ, et al. Enzymatic prenylation and oxime ligation for the synthesis of stable and homogeneous protein-drug conjugates for targeted therapy. Angew Chem Int Ed Engl. 2015 Oct 5;54(41):12020-4. [Content Brief]
[3]. Kim EG, et al. Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted CancerTherapeutics. [Content Brief]
[4]. Doronina SO, et al. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem. 2006 Jan-Feb;17(1):114-24. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 1.3264 mL | 6.6318 mL | 13.2637 mL | 33.1591 mL |
| 5 mM | 0.2653 mL | 1.3264 mL | 2.6527 mL | 6.6318 mL | |
| 10 mM | 0.1326 mL | 0.6632 mL | 1.3264 mL | 3.3159 mL | |
| 15 mM | 0.0884 mL | 0.4421 mL | 0.8842 mL | 2.2106 mL | |
| 20 mM | 0.0663 mL | 0.3316 mL | 0.6632 mL | 1.6580 mL | |
| 25 mM | 0.0531 mL | 0.2653 mL | 0.5305 mL | 1.3264 mL | |
| 30 mM | 0.0442 mL | 0.2211 mL | 0.4421 mL | 1.1053 mL | |
| 40 mM | 0.0332 mL | 0.1658 mL | 0.3316 mL | 0.8290 mL | |
| 50 mM | 0.0265 mL | 0.1326 mL | 0.2653 mL | 0.6632 mL | |
| 60 mM | 0.0221 mL | 0.1105 mL | 0.2211 mL | 0.5527 mL | |
| 80 mM | 0.0166 mL | 0.0829 mL | 0.1658 mL | 0.4145 mL | |
| 100 mM | 0.0133 mL | 0.0663 mL | 0.1326 mL | 0.3316 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Powered by Bioz